MovDisordV3, PascalFrancis, Corpus, bibRecord, 002824

Interaction of levodopa and cues on voluntary reaching in Parkinson's disease

Identifieur interne : 002824 ( PascalFrancis/Corpus ); précédent : 002823; suivant : 002825

Interaction of levodopa and cues on voluntary reaching in Parkinson's disease

Auteurs : Valerie E. Kelly ; Allie S. Hyngstrom ; Melissa M. Rundle ; Amy J. Bastian

Source :

Movement disorders [ 0885-3185 ] ; 2002.

RBID : Pascal:02-0206587

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Lévodopa, Chimiothérapie, Antiparkinsonien, Cinématique, Mouvement corporel, Atteignabilité, Stimulus lumineux, Evaluation performance, Traitement, Personne âgée, Bradykinésie.

English descriptors

KwdEn :
- Antiparkinson agent, Body movement, Chemotherapy, Elderly, Kinematics, Levodopa, Light stimulus, Parkinson disease, Performance evaluation, Reachability, Treatment.

Abstract

The bradykinesia associated with Parkinson's disease (PD) can be improved by both levodopa and the use of external cues. We examined the combined effect of levodopa and external cueing on the voluntary reaching movements of individuals with PD. Nine subjects with PD and nine matched controls were studied reaching to a ball target. Subjects with PD were studied after being off levodopa overnight and again on their morning dose. Kinematic data were collected as all subjects made both accurate and fast reaches under two different cue conditions: noncued (self-initiated) and cued (triggered by a light). Subjects with PD reached more slowly than controls under all conditions. PD subjects increased their reach velocity and decreased movement time after taking levodopa and also when moving to a cue. However, the effects of levodopa and cueing were not additive. Instead, levodopa improved reach velocity to a greater extent in the noncued vs. cued condition. We also found that levodopa improved accurate (self-paced) reaches more than fast reaches. These data suggest that levodopa may preferentially improve voluntary reaches that are more internally generated.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 17`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Interaction of levodopa and cues on voluntary reaching in Parkinson's disease`
A11	`01`	`1`		`@1 KELLY (Valerie E.)`
A11	`02`	`1`		`@1 HYNGSTROM (Allie S.)`
A11	`03`	`1`		`@1 RUNDLE (Melissa M.)`
A11	`04`	`1`		`@1 BASTIAN (Amy J.)`
A14	`01`			`@1 Program in Physical Therapy, Washington University School of Medicine @2 St. Louis, Missouri @3 USA @Z 1 aut. @Z 2 aut. @Z 4 aut.`
A14	`02`			`@1 Movement Disorders Center, Washington University School of Medicine @2 St. Louis, Missouri @3 USA @Z 3 aut. @Z 4 aut.`
A14	`03`			`@1 Anatomy and Neurobiology, Washington University School of Medicine @2 St. Louis, Missouri @3 USA @Z 4 aut.`
A20				`@1 38-44`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000100147290070`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 15 ref.`
A47	`01`	`1`		`@0 02-0206587`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The bradykinesia associated with Parkinson's disease (PD) can be improved by both levodopa and the use of external cues. We examined the combined effect of levodopa and external cueing on the voluntary reaching movements of individuals with PD. Nine subjects with PD and nine matched controls were studied reaching to a ball target. Subjects with PD were studied after being off levodopa overnight and again on their morning dose. Kinematic data were collected as all subjects made both accurate and fast reaches under two different cue conditions: noncued (self-initiated) and cued (triggered by a light). Subjects with PD reached more slowly than controls under all conditions. PD subjects increased their reach velocity and decreased movement time after taking levodopa and also when moving to a cue. However, the effects of levodopa and cueing were not additive. Instead, levodopa improved reach velocity to a greater extent in the noncued vs. cued condition. We also found that levodopa improved accurate (self-paced) reaches more than fast reaches. These data suggest that levodopa may preferentially improve voluntary reaches that are more internally generated.
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 04`
C03	`02`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 04`
C03	`02`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Chimiothérapie @5 05`
C03	`03`	`X`	`ENG`	`@0 Chemotherapy @5 05`
C03	`03`	`X`	`SPA`	`@0 Quimioterapia @5 05`
C03	`04`	`X`	`FRE`	`@0 Antiparkinsonien @5 06`
C03	`04`	`X`	`ENG`	`@0 Antiparkinson agent @5 06`
C03	`04`	`X`	`SPA`	`@0 Antiparkinsoniano @5 06`
C03	`05`	`X`	`FRE`	`@0 Cinématique @5 07`
C03	`05`	`X`	`ENG`	`@0 Kinematics @5 07`
C03	`05`	`X`	`SPA`	`@0 Cinemática @5 07`
C03	`06`	`X`	`FRE`	`@0 Mouvement corporel @5 08`
C03	`06`	`X`	`ENG`	`@0 Body movement @5 08`
C03	`06`	`X`	`SPA`	`@0 Movimiento corporal @5 08`
C03	`07`	`X`	`FRE`	`@0 Atteignabilité @5 10`
C03	`07`	`X`	`ENG`	`@0 Reachability @5 10`
C03	`07`	`X`	`SPA`	`@0 Asequibilidad @5 10`
C03	`08`	`X`	`FRE`	`@0 Stimulus lumineux @5 13`
C03	`08`	`X`	`ENG`	`@0 Light stimulus @5 13`
C03	`08`	`X`	`SPA`	`@0 Estímulo luminoso @5 13`
C03	`09`	`X`	`FRE`	`@0 Evaluation performance @5 17`
C03	`09`	`X`	`ENG`	`@0 Performance evaluation @5 17`
C03	`09`	`X`	`SPA`	`@0 Evaluación prestación @5 17`
C03	`10`	`X`	`FRE`	`@0 Traitement @5 18`
C03	`10`	`X`	`ENG`	`@0 Treatment @5 18`
C03	`10`	`X`	`SPA`	`@0 Tratamiento @5 18`
C03	`11`	`X`	`FRE`	`@0 Personne âgée @5 20`
C03	`11`	`X`	`ENG`	`@0 Elderly @5 20`
C03	`11`	`X`	`SPA`	`@0 Anciano @5 20`
C03	`12`	`X`	`FRE`	`@0 Bradykinésie @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`03`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`04`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`07`	`X`	`FRE`	`@0 Trouble neurologique @5 42`
C07	`07`	`X`	`ENG`	`@0 Neurological disorder @5 42`
C07	`07`	`X`	`SPA`	`@0 Trastorno neurológico @5 42`
N21				`@1 119`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 02-0206587 INIST
ET :	Interaction of levodopa and cues on voluntary reaching in Parkinson's disease
AU :	KELLY (Valerie E.); HYNGSTROM (Allie S.); RUNDLE (Melissa M.); BASTIAN (Amy J.)
AF :	Program in Physical Therapy, Washington University School of Medicine/St. Louis, Missouri/Etats-Unis (1 aut., 2 aut., 4 aut.); Movement Disorders Center, Washington University School of Medicine/St. Louis, Missouri/Etats-Unis (3 aut., 4 aut.); Anatomy and Neurobiology, Washington University School of Medicine/St. Louis, Missouri/Etats-Unis (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 1; Pp. 38-44; Bibl. 15 ref.
LA :	Anglais
EA :	The bradykinesia associated with Parkinson's disease (PD) can be improved by both levodopa and the use of external cues. We examined the combined effect of levodopa and external cueing on the voluntary reaching movements of individuals with PD. Nine subjects with PD and nine matched controls were studied reaching to a ball target. Subjects with PD were studied after being off levodopa overnight and again on their morning dose. Kinematic data were collected as all subjects made both accurate and fast reaches under two different cue conditions: noncued (self-initiated) and cued (triggered by a light). Subjects with PD reached more slowly than controls under all conditions. PD subjects increased their reach velocity and decreased movement time after taking levodopa and also when moving to a cue. However, the effects of levodopa and cueing were not additive. Instead, levodopa improved reach velocity to a greater extent in the noncued vs. cued condition. We also found that levodopa improved accurate (self-paced) reaches more than fast reaches. These data suggest that levodopa may preferentially improve voluntary reaches that are more internally generated.
CC :	002B17G
FD :	Parkinson maladie; Lévodopa; Chimiothérapie; Antiparkinsonien; Cinématique; Mouvement corporel; Atteignabilité; Stimulus lumineux; Evaluation performance; Traitement; Personne âgée; Bradykinésie
FG :	Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique
ED :	Parkinson disease; Levodopa; Chemotherapy; Antiparkinson agent; Kinematics; Body movement; Reachability; Light stimulus; Performance evaluation; Treatment; Elderly
EG :	Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder
SD :	Parkinson enfermedad; Levodopa; Quimioterapia; Antiparkinsoniano; Cinemática; Movimiento corporal; Asequibilidad; Estímulo luminoso; Evaluación prestación; Tratamiento; Anciano
LO :	INIST-20953.354000100147290070
ID :	02-0206587

Links to Exploration step

Pascal:02-0206587

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Interaction of levodopa and cues on voluntary reaching in Parkinson's disease</title>
<author><name sortKey="Kelly, Valerie E" sort="Kelly, Valerie E" uniqKey="Kelly V" first="Valerie E." last="Kelly">Valerie E. Kelly</name>
<affiliation><inist:fA14 i1="01"><s1>Program in Physical Therapy, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hyngstrom, Allie S" sort="Hyngstrom, Allie S" uniqKey="Hyngstrom A" first="Allie S." last="Hyngstrom">Allie S. Hyngstrom</name>
<affiliation><inist:fA14 i1="01"><s1>Program in Physical Therapy, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rundle, Melissa M" sort="Rundle, Melissa M" uniqKey="Rundle M" first="Melissa M." last="Rundle">Melissa M. Rundle</name>
<affiliation><inist:fA14 i1="02"><s1>Movement Disorders Center, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bastian, Amy J" sort="Bastian, Amy J" uniqKey="Bastian A" first="Amy J." last="Bastian">Amy J. Bastian</name>
<affiliation><inist:fA14 i1="01"><s1>Program in Physical Therapy, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Movement Disorders Center, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Anatomy and Neurobiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0206587</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0206587 INIST</idno>
<idno type="RBID">Pascal:02-0206587</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002824</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Interaction of levodopa and cues on voluntary reaching in Parkinson's disease</title>
<author><name sortKey="Kelly, Valerie E" sort="Kelly, Valerie E" uniqKey="Kelly V" first="Valerie E." last="Kelly">Valerie E. Kelly</name>
<affiliation><inist:fA14 i1="01"><s1>Program in Physical Therapy, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hyngstrom, Allie S" sort="Hyngstrom, Allie S" uniqKey="Hyngstrom A" first="Allie S." last="Hyngstrom">Allie S. Hyngstrom</name>
<affiliation><inist:fA14 i1="01"><s1>Program in Physical Therapy, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rundle, Melissa M" sort="Rundle, Melissa M" uniqKey="Rundle M" first="Melissa M." last="Rundle">Melissa M. Rundle</name>
<affiliation><inist:fA14 i1="02"><s1>Movement Disorders Center, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bastian, Amy J" sort="Bastian, Amy J" uniqKey="Bastian A" first="Amy J." last="Bastian">Amy J. Bastian</name>
<affiliation><inist:fA14 i1="01"><s1>Program in Physical Therapy, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Movement Disorders Center, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Anatomy and Neurobiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Body movement</term>
<term>Chemotherapy</term>
<term>Elderly</term>
<term>Kinematics</term>
<term>Levodopa</term>
<term>Light stimulus</term>
<term>Parkinson disease</term>
<term>Performance evaluation</term>
<term>Reachability</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Cinématique</term>
<term>Mouvement corporel</term>
<term>Atteignabilité</term>
<term>Stimulus lumineux</term>
<term>Evaluation performance</term>
<term>Traitement</term>
<term>Personne âgée</term>
<term>Bradykinésie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The bradykinesia associated with Parkinson's disease (PD) can be improved by both levodopa and the use of external cues. We examined the combined effect of levodopa and external cueing on the voluntary reaching movements of individuals with PD. Nine subjects with PD and nine matched controls were studied reaching to a ball target. Subjects with PD were studied after being off levodopa overnight and again on their morning dose. Kinematic data were collected as all subjects made both accurate and fast reaches under two different cue conditions: noncued (self-initiated) and cued (triggered by a light). Subjects with PD reached more slowly than controls under all conditions. PD subjects increased their reach velocity and decreased movement time after taking levodopa and also when moving to a cue. However, the effects of levodopa and cueing were not additive. Instead, levodopa improved reach velocity to a greater extent in the noncued vs. cued condition. We also found that levodopa improved accurate (self-paced) reaches more than fast reaches. These data suggest that levodopa may preferentially improve voluntary reaches that are more internally generated.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Interaction of levodopa and cues on voluntary reaching in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KELLY (Valerie E.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HYNGSTROM (Allie S.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>RUNDLE (Melissa M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BASTIAN (Amy J.)</s1>
</fA11>
<fA14 i1="01"><s1>Program in Physical Therapy, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Movement Disorders Center, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Anatomy and Neurobiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>38-44</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000100147290070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>15 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0206587</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The bradykinesia associated with Parkinson's disease (PD) can be improved by both levodopa and the use of external cues. We examined the combined effect of levodopa and external cueing on the voluntary reaching movements of individuals with PD. Nine subjects with PD and nine matched controls were studied reaching to a ball target. Subjects with PD were studied after being off levodopa overnight and again on their morning dose. Kinematic data were collected as all subjects made both accurate and fast reaches under two different cue conditions: noncued (self-initiated) and cued (triggered by a light). Subjects with PD reached more slowly than controls under all conditions. PD subjects increased their reach velocity and decreased movement time after taking levodopa and also when moving to a cue. However, the effects of levodopa and cueing were not additive. Instead, levodopa improved reach velocity to a greater extent in the noncued vs. cued condition. We also found that levodopa improved accurate (self-paced) reaches more than fast reaches. These data suggest that levodopa may preferentially improve voluntary reaches that are more internally generated.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Cinématique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Kinematics</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Cinemática</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Mouvement corporel</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Body movement</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Movimiento corporal</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Atteignabilité</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Reachability</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Asequibilidad</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Stimulus lumineux</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Light stimulus</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estímulo luminoso</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Evaluation performance</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Performance evaluation</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Evaluación prestación</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Traitement</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Treatment</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Personne âgée</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Elderly</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Anciano</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Bradykinésie</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>42</s5>
</fC07>
<fN21><s1>119</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 02-0206587 INIST</NO>
<ET>Interaction of levodopa and cues on voluntary reaching in Parkinson's disease</ET>
<AU>KELLY (Valerie E.); HYNGSTROM (Allie S.); RUNDLE (Melissa M.); BASTIAN (Amy J.)</AU>
<AF>Program in Physical Therapy, Washington University School of Medicine/St. Louis, Missouri/Etats-Unis (1 aut., 2 aut., 4 aut.); Movement Disorders Center, Washington University School of Medicine/St. Louis, Missouri/Etats-Unis (3 aut., 4 aut.); Anatomy and Neurobiology, Washington University School of Medicine/St. Louis, Missouri/Etats-Unis (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 1; Pp. 38-44; Bibl. 15 ref.</SO>
<LA>Anglais</LA>
<EA>The bradykinesia associated with Parkinson's disease (PD) can be improved by both levodopa and the use of external cues. We examined the combined effect of levodopa and external cueing on the voluntary reaching movements of individuals with PD. Nine subjects with PD and nine matched controls were studied reaching to a ball target. Subjects with PD were studied after being off levodopa overnight and again on their morning dose. Kinematic data were collected as all subjects made both accurate and fast reaches under two different cue conditions: noncued (self-initiated) and cued (triggered by a light). Subjects with PD reached more slowly than controls under all conditions. PD subjects increased their reach velocity and decreased movement time after taking levodopa and also when moving to a cue. However, the effects of levodopa and cueing were not additive. Instead, levodopa improved reach velocity to a greater extent in the noncued vs. cued condition. We also found that levodopa improved accurate (self-paced) reaches more than fast reaches. These data suggest that levodopa may preferentially improve voluntary reaches that are more internally generated.</EA>
<CC>002B17G</CC>
<FD>Parkinson maladie; Lévodopa; Chimiothérapie; Antiparkinsonien; Cinématique; Mouvement corporel; Atteignabilité; Stimulus lumineux; Evaluation performance; Traitement; Personne âgée; Bradykinésie</FD>
<FG>Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique</FG>
<ED>Parkinson disease; Levodopa; Chemotherapy; Antiparkinson agent; Kinematics; Body movement; Reachability; Light stimulus; Performance evaluation; Treatment; Elderly</ED>
<EG>Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder</EG>
<SD>Parkinson enfermedad; Levodopa; Quimioterapia; Antiparkinsoniano; Cinemática; Movimiento corporal; Asequibilidad; Estímulo luminoso; Evaluación prestación; Tratamiento; Anciano</SD>
<LO>INIST-20953.354000100147290070</LO>
<ID>02-0206587</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002824 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002824 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0206587
   |texte=   Interaction of levodopa and cues on voluntary reaching in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Interaction of levodopa and cues on voluntary reaching in Parkinson's disease

Interaction of levodopa and cues on voluntary reaching in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri